Prospective, multicenter, double-blind, randomized, cross-over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidemia in children with persisting proteinuria
Completed
- Conditions
- Glomerular diseases with proteinuriaNutritional, Metabolic, EndocrineProteinuria, hyperlipidemia
- Registration Number
- ISRCTN06912061
- Lead Sponsor
- Genzyme Europe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Children aged 2-18 years, with persisting proteinuria and hypercholesterolemia.
Exclusion Criteria
1. Chronic renal insufficiency (glomerular filtration rate [GFR] <40 ml/min)
2. Genetic forms of hyperlipidemia
3. Hyperlipidemia due to other causes
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method